Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Latest estimates indicate that the number of patients affected by cancer will increase dramatically through the middle of the century across all regions of the world. At the same time, the innovation ecosystem that discovers, develops, and delivers breakthrough therapies in entire new areas of science is operating near peak levels. Rising incidence, increasing numbers of treated patients, and the resulting expected growth in spending in this area will trigger an array of complex challenges over the next several years that are reflected in the trends highlighted in this report.
Our research profiles latest available data on cancer incidence and survival, the current state of research and development activity in oncology, including key mechanisms, targets and cancer types being investigated. We also look at metrics of clinical development productivity. As more novel cancer medicines are launched, patient access and use of those drugs vary widely around the world and by some measures the gaps between the science and patients is expanding. Trends in the use of novel mechanisms in specific cancer types are reported here as well as current expectations for how spending dynamics will play out over the next five years.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.